Advertisement

Use of proton pump inhibitors and subsequent risk of celiac disease

  • Benjamin Lebwohl
    Affiliations
    Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA

    Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden
    Search for articles by this author
  • Stuart J. Spechler
    Affiliations
    Division of Gastroenterology, Department of Internal Medicine, VA North Texas Healthcare System and UT Southwestern Medical Center, Dallas, TX, USA
    Search for articles by this author
  • Timothy C. Wang
    Affiliations
    Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Search for articles by this author
  • Peter H.R. Green
    Affiliations
    Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Search for articles by this author
  • Jonas F. Ludvigsson
    Correspondence
    Corresponding author at: Department of Pediatrics, Örebro University Hospital, Sweden. Tel.: +46 019 6021000; fax: +46 019 187915.
    Affiliations
    Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden

    Department of Pediatrics, Örebro University Hospital, Sweden
    Search for articles by this author
Published:September 16, 2013DOI:https://doi.org/10.1016/j.dld.2013.08.128

      Abstract

      Background

      The prevalence of celiac disease and the use of medications that inhibit acid secretion have both increased in recent decades.

      Aim

      To explore the association between antisecretory medication exposure and subsequent development of celiac disease.

      Methods

      In this population-based case control study, we identified patients with celiac disease diagnosed at all pathology departments in Sweden from July 2005 through February 2008. Patients were matched by age and gender with up to 5 controls. We identified prior prescriptions for proton pump inhibitors and histamine-2 receptor antagonists in all subjects. We used conditional logistic regression to measure the association between these prescriptions and the subsequent diagnosis of celiac disease.

      Results

      Prior proton pump inhibitor prescription was strongly associated with celiac disease (OR 4.79; 95% CI 4.17–5.51). Patients prescribed both proton pump inhibitors and histamine-2 receptor antagonists had a higher risk of celiac disease (OR 5.96; 95% CI 3.58–9.91) than those prescribed proton pump inhibitors alone (OR 4.91; 95% CI 4.26–5.66) or histamine-2 receptor antagonists alone (OR 4.16; 95% CI 2.89–5.99).

      Conclusions

      Exposure to antisecretory medications is associated with a subsequent diagnosis of celiac disease. The persistence of this association after excluding prescriptions in the year preceding the celiac disease diagnosis suggests a causal relationship.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Green P.H.
        • Cellier C.
        Celiac disease.
        New England Journal of Medicine. 2007; 357: 1731-1743
        • Rubio-Tapia A.
        • Kyle R.A.
        • Kaplan E.L.
        • et al.
        Increased prevalence and mortality in undiagnosed celiac disease.
        Gastroenterology. 2009; 137: 88-93
        • Catassi C.
        • Kryszak D.
        • Bhatti B.
        • et al.
        Natural history of celiac disease autoimmunity in a USA cohort followed since 1974.
        Annals of Medicine. 2010; 42: 530-538
        • Lohi S.
        • Mustalahti K.
        • Kaukinen K.
        • et al.
        Increasing prevalence of coeliac disease over time.
        Alimentary Pharmacology and Therapeutics. 2007; 26: 1217-1225
        • Kupfer S.S.
        • Jabri B.
        Pathophysiology of celiac disease.
        Gastrointestinal Endoscopy Clinics of North America. 2012; 22: 639-660
        • Ivarsson A.
        • Persson L.A.
        • Nystrom L.
        • et al.
        Epidemic of coeliac disease in Swedish children.
        Acta Paediatrica. 2000; 89: 165-171
        • Welander A.
        • Tjernberg A.R.
        • Montgomery S.M.
        • et al.
        Infectious disease and risk of later celiac disease in childhood.
        Pediatrics. 2010; 125: e530-e536
        • Vilppula A.
        • Kaukinen K.
        • Luostarinen L.
        • et al.
        Increasing prevalence and high incidence of celiac disease in elderly people: a population-based study.
        BMC Gastroenterology. 2009; 9: 49
        • Mukherjee R.
        • Egbuna I.
        • Brar P.
        • et al.
        Celiac disease: similar presentations in the elderly and young adults.
        Digestive Diseases and Sciences. 2010; 55: 3147-3153
        • Murray J.A.
        • Van Dyke C.
        • Plevak M.F.
        • et al.
        Trends in the identification and clinical features of celiac disease in a North American community, 1950–2001.
        Clin Gastroenterol Hepatol. 2003; 1: 19-27
        • Khalili H.
        • Huang E.S.
        • Jacobson B.C.
        • et al.
        Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.
        British Medical Journal. 2012; 344: 372-377
        • Roberts N.B.
        Review article: human pepsins – their multiplicity, function and role in reflux disease.
        Alimentary Pharmacology and Therapeutics. 2006; 24: 2-9
        • Mullin J.M.
        • Valenzano M.C.
        • Whitby M.
        • et al.
        Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase.
        Alimentary Pharmacology and Therapeutics. 2008; 28: 1317-1325
        • Hopkins A.M.
        • McDonnell C.
        • Breslin N.P.
        • et al.
        Omeprazole increases permeability across isolated rat gastric mucosa pre-treated with an acid secretagogue.
        Journal of Pharmacy and Pharmacology. 2002; 54: 341-347
        • Ludvigsson J.F.
        • Montgomery S.M.
        • Ekbom A.
        • et al.
        Small-intestinal histopathology and mortality risk in celiac disease.
        Journal of the American Medical Association. 2009; 302: 1171-1178
        • Ludvigsson J.F.
        • Brandt L.
        • Montgomery S.M.
        • et al.
        Validation study of villous atrophy and small intestinal inflammation in Swedish biopsy registers.
        BMC Gastroenterology. 2009; 9: 19-31
        • Ludvigsson J.F.
        • Otterblad-Olausson P.
        • Pettersson B.U.
        • et al.
        The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research.
        European Journal of Epidemiology. 2009; 24: 659-667
        • Wettermark B.
        • Hammar N.
        • Fored C.M.
        • et al.
        The new Swedish Prescribed Drug Register – opportunities for pharmacoepidemiological research and experience from the first six months.
        Pharmacoepidemiology and Drug Safety. 2007; 16: 726-735
        • Stephansson O.
        • Granath F.
        • Svensson T.
        • et al.
        Drug use during pregnancy in Sweden – assessed by the Prescribed Drug Register and the Medical Birth Register.
        Clinical Epidemiology. 2011; 3: 43-50
        • Ljung R.
        • Ruck C.
        • Mattsson F.
        • et al.
        Selective serotonin reuptake inhibitors and the risk of acute pancreatitis: a Swedish population-based case–control study.
        Journal of Clinical Psychopharmacology. 2012; 32: 336-340
        • Jonasson C.
        • Hatlebakk J.G.
        • Lundell L.
        • et al.
        Association between adherence to concomitant proton pump inhibitor therapy in current NSAID users and upper gastrointestinal complications.
        European Journal of Gastroenterology and Hepatology. 2013; 25: 531-538
        • Lo W.
        • Sano K.
        • Lebwohl B.
        • et al.
        Changing presentation of adult celiac disease.
        Digestive Diseases and Sciences. 2003; 48: 395-398
        • Stene L.C.
        • Honeyman M.C.
        • Hoffenberg E.J.
        • et al.
        Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study.
        American Journal of Gastroenterology. 2006; 101: 2333-2340
        • Marild K.
        • Stephansson O.
        • Montgomery S.
        • et al.
        Pregnancy outcome and risk of celiac disease in offspring: a nationwide case–control study.
        Gastroenterology. 2012; 142: 39-45
        • Lebwohl B.
        • Green P.H.
        • Murray J.A.
        • et al.
        Season of birth in a nationwide cohort of coeliac disease patients.
        Archives of Disease in Childhood. 2013; 98: 48-51
        • Tanpowpong P.
        • Obuch J.C.
        • Jiang H.
        • et al.
        Multicenter study on season of birth and celiac disease: evidence for a new theoretical model of pathogenesis.
        Journal of Pediatrics. 2013; 162: 501-504
        • Ament P.W.
        • Dicola D.B.
        • James M.E.
        Reducing adverse effects of proton pump inhibitors.
        American Family Physician. 2012; 86: 66-70
        • Miner Jr., P.
        • Katz P.O.
        • Chen Y.
        • et al.
        Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
        American Journal of Gastroenterology. 2003; 98: 2616-2620
        • Spechler S.J.
        • Sharma P.
        • Traxler B.
        • et al.
        Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial.
        American Journal of Gastroenterology. 2006; 101: 1964-1971
        • Untersmayr E.
        • Scholl I.
        • Swoboda I.
        • et al.
        Antacid medication inhibits digestion of dietary proteins and causes food allergy: a fish allergy model in BALB/c mice.
        Journal of Allergy and Clinical Immunology. 2003; 112: 616-623
        • Scholl I.
        • Untersmayr E.
        • Bakos N.
        • et al.
        Antiulcer drugs promote oral sensitization and hypersensitivity to hazelnut allergens in BALB/c mice and humans.
        American Journal of Clinical Nutrition. 2005; 81: 154-160
        • Untersmayr E.
        • Bakos N.
        • Scholl I.
        • et al.
        Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients.
        FASEB Journal. 2005; 19: 656-658
        • Pittman F.E.
        • Pollitt R.J.
        Studies of jejunal mucosal digestion of peptic-tryptic digests of wheat protein in coeliac disease.
        Gut. 1966; 7: 368-371
        • Keck B.
        • Kohler P.
        • Wieser H.
        Disulphide bonds in wheat gluten: cystine peptides derived from gluten proteins following peptic and thermolytic digestion.
        Zeitschrift fur Lebensmittel-Untersuchung und -Forschung. 1995; 200: 432-439
        • Shan L.
        • Molberg O.
        • Parrot I.
        • et al.
        Structural basis for gluten intolerance in celiac sprue.
        Science. 2002; 297: 2275-2279
        • Snook J.A.
        • Dwyer L.
        • Lee-Elliott C.
        • et al.
        Adult coeliac disease and cigarette smoking.
        Gut. 1996; 39: 60-62
        • Kaufmann D.
        • Wilder-Smith C.H.
        • Kempf M.
        • et al.
        Cigarette smoking, gastric acidity and peptic ulceration. What are the relationships?.
        Digestive Diseases and Sciences. 1990; 35: 1482-1487
        • Kedika R.R.
        • Souza R.F.
        • Spechler S.J.
        Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications.
        Digestive Diseases and Sciences. 2009; 54: 2312-2317
        • Garcia Rodriguez L.A.
        • Ruigomez A.
        • Panes J.
        Use of acid-suppressing drugs and the risk of bacterial gastroenteritis.
        Clinical Gastroenterology and Hepatology. 2007; 5: 1418-1423
        • Leonard J.
        • Marshall J.K.
        • Moayyedi P.
        Systematic review of the risk of enteric infection in patients taking acid suppression.
        American Journal of Gastroenterology. 2007; 102: 2047-2056
        • Keszthelyi D.
        • Jansen S.V.
        • Schouten G.A.
        • et al.
        Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case–control study.
        Alimentary Pharmacology and Therapeutics. 2010; 32: 1124-1128
        • Green P.H.
        • Yang J.
        • Cheng J.
        • et al.
        An association between microscopic colitis and celiac disease.
        Clinical Gastroenterology and Hepatology. 2009; 7: 1210-1216
        • Theisen J.
        • Nehra D.
        • Citron D.
        • et al.
        Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids.
        Journal of Gastrointestinal Surgery. 2000; 4: 50-54
        • Williams C.
        • McColl K.E.
        Review article: proton pump inhibitors and bacterial overgrowth.
        Alimentary Pharmacology and Therapeutics. 2006; 23: 3-10
        • Garcia-Mazcorro J.F.
        • Suchodolski J.S.
        • Jones K.R.
        • et al.
        Effect of the proton pump inhibitor omeprazole on the gastrointestinal bacterial microbiota of healthy dogs.
        FEMS Microbiology Ecology. 2012; 80: 624-636